Multicenter Analysis of Adverse Events Associated with Induction Chemotherapy in Metastatic Testicular Tumors: Age-Based Comparison of Patients Aged 50 Years and Older Versus Younger Than 50 Years

Multicenter Analysis of Adverse Events Associated with Induction Chemotherapy in Metastatic Testicular Tumors: Age-Based Comparison of Patients Aged 50 Years and Older Versus Younger Than 50 Years - MATCH-50 (Metastatic testicular tumor Adverse event study by CHemotherapy in patients under/over 50)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058123

Enrollment

183

Registered

2026-01-01

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic testicular tumors

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)Patients with histologically proven testicular tumors 2)Patients with unresectable tumors or metastases to other organs 3)Patients who have received BEP, EP, or VIP therapy

Exclusion criteria

Exclusion criteria: 1) Patients with active cancer originating in other organs at the start of BEP, EP, or VIP therapy 2) Patients with incomplete data or who cannot be followed up

Design outcomes

Primary

Measure	Time frame
Types and incidence of adverse events associated with BEP, EP, and VIP therapy	—

Secondary

Measure	Time frame
1)Incidence of regimen changes in BEP, EP, and VIP therapy (proportion of patients who experienced a reduction in anticancer drug dosage, proportion of patients who experienced a skip, and proportion of patients who experienced a skip) 2)Response rate (PR+CR) and CR response rate in BEP, EP, and VIP therapy 3)Overall survival rate (OS, 1-year survival rate, and 3-year survival rate) 4) Disease-specific survival rate (CSS, 1-year survival rate, and 3-year survival rate)	—

Measure

Time frame

1)Incidence of regimen changes in BEP, EP, and VIP therapy (proportion of patients who experienced a reduction in anticancer drug dosage, proportion of patients who experienced a skip, and proportion of patients who experienced a skip) 2)Response rate (PR+CR) and CR response rate in BEP, EP, and VIP therapy 3)Overall survival rate (OS, 1-year survival rate, and 3-year survival rate) 4) Disease-specific survival rate (CSS, 1-year survival rate, and 3-year survival rate)

—

Countries

Japan

Contacts

Public ContactKATAMI AKINOBU

International University of Health and Welfare Narita Hospital Renal and Urological Surgery

a-katami@ihwg.jp0476-35-5600

Outcome results